Physician profile
Suzanne M Lind
NPI 1437250644
$18,398.40
in general payments reported to CMS, 2019-2025
18 companies · $12K in 2025
The $12K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $555 · 2021: $822 · 2022: $1,030 · 2023: $1,091 · 2024: $2,167 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,030 · Food and Beverage: $6,170 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,030.00 |
| Food and Beverage | $6,170.27 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11,449.46 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,817.58 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,211.49 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,108.98 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $956.19 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $439.48 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $379.73 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $314.21 | 2021-2025 | Caplyta |
| Lundbeck LLC | $205.00 | 2020-2025 | Abilify Asimtufii, Rexulti |
| Luye Pharma (USA) Ltd. | $135.94 | 2025 | Erzofri Extended-Release |
| Vanda Pharmaceuticals INC. | $105.21 | 2019-2022 | |
| Almatica Pharma LLC | $100.68 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Indivior INC. | $54.55 | 2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $48.01 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $27.38 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $16.57 | 2023 | Igalmi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Lind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.